SRR819346
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.751
- INTERFERON_GAMMA_RESPONSE+0.678
- TNFA_SIGNALING_VIA_NFKB+0.598
- IL6_JAK_STAT3_SIGNALING+0.593
- ALLOGRAFT_REJECTION+0.504
- INFLAMMATORY_RESPONSE+0.498
- ANGIOGENESIS+0.430
- IL2_STAT5_SIGNALING+0.419
- COMPLEMENT+0.397
- APOPTOSIS+0.346
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.361
- HEDGEHOG_SIGNALING-0.333
- BILE_ACID_METABOLISM-0.208
- ADIPOGENESIS-0.198
- FATTY_ACID_METABOLISM-0.189
- PROTEIN_SECRETION-0.186
- PEROXISOME-0.182
- MITOTIC_SPINDLE-0.161
- CHOLESTEROL_HOMEOSTASIS-0.158
- UV_RESPONSE_DN-0.077
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR817658 | GTEX | — | 0.986 |
| 2 | SRR810571 | GTEX | — | 0.957 |
| 3 | BS_ENKG5GF3 | Neurofibroma | — | 0.886 |
| 4 | BS_3J85TTZM | MPNST | — | 0.880 |
| 5 | TCGA-63-A5MM-01A-11R-A26W-07 | — | cohortA1 | 0.873 |
| 6 | TCGA-FD-A62N-01A-11R-A30C-07 | — | — | 0.869 |
| 7 | BS_RQSKD7PN | MPNST | — | 0.868 |
| 8 | SRR8613765 | — | D | 0.868 |
| 9 | SRR1445895 | GTEX | — | 0.860 |
| 10 | SRR821019 | GTEX | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.751 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.678 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.598 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.593 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.504 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.498 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.419 | Idelalisib | — uncovered |
| COMPLEMENT | 0.397 | Inavolisib | — uncovered |
| APOPTOSIS | 0.346 | Idelalisib | — uncovered |
| HYPOXIA | 0.338 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.329 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.313 | Inavolisib | — uncovered |
| COAGULATION | 0.287 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.277 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.268 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.233 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.229 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.222 | Inavolisib | — uncovered |